Previous 10 | Next 10 |
Recent news releases related news releases and press releases from 11/08/23 07:00:26 on US and Canada Markets.
Third quarter revenues of $59.2 million, in line with previous guidance Third quarter GAAP net loss of $8.2 million; non-GAAP net loss of $3.4 million Impressions and consumables revenues both continued to grow year-over-year System sales increased quarter-over-quarter on continued co...
BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea manag...
BOTHELL, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate at th...
HONG KONG, Nov. 08, 2023 (GLOBE NEWSWIRE) -- UCLOUDLINK GROUP INC. (“UCLOUDLINK” or the “Company”) (NASDAQ: UCL), the world’s first and leading mobile data traffic sharing marketplace, today announced that it will report its unaudited financial results for the t...
Accelerating Margins and Updating Earnings Estimates Generating Strong Cash Flow and Improving Leverage Gaining Product Category Share Reynolds Consumer Products Inc. (the “Company”) (Nasdaq: REYN) today reported financial results for the third qu...
Fourth Consecutive Quarter of Year-Over-Year Gross Originations Growth Fourth Quarter Outlook Includes Continued Year-Over-Year Growth for Gross Originations, Revenue and Adjusted EBITDA PLANO, Texas, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Katapult Holdings, Inc. (“Katapult ...
Median overall survival of 15.5 months with BXCL701 + KEYTRUDA® (pembrolizumab), compared to 9.6 months with checkpoint inhibitor monotherapy in late-line refractory patients in separate Phase 2 trial 1 59% of studied patients alive at one year following treatment with BX...
SARNIA, Ontario, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“ Aduro ” or the “ Company ”) (CSE: ACT ) (OTCQX: ACTHF ) (FSE: 9D50 ), a Canadian developer of patented water-based technologies to chemically recycle plastic...
- Q3 Total Revenue and Software Revenue of $35.1 and $20.4 million, respectively - - ARR (1) of $99 million from 3,536 Total Software Products & Services Customers (1) , including $48 million from subscription-based customers (1) - - Over $24 million of...
-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUP TM and more than 400 patients initiating therapy as of September 30 -- -- LUMRYZ to be ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
65.81%Change Percent:
Jaguar Health Inc. Company Name:
JAGX Stock Symbol:
NASDAQ Market:
jaguar.health Website: